pharma news

News

Sanofi's bispecific lunsekimig has mixed readouts in phase 2

Sanofi's IL-13 and TSLP-targeting bispecific lunsekimig wins two, loses one, in readouts from its midstage clinical trials programme.

News

Amgen scientists working in the lab, one woman and one man

Amgen scores with new thyroid eye disease formulation

Can Amgen's subcutaneous version of Tepezza inject renewed growth into the thyroid eye disease blockbuster?

News

Neurocrine pays $2.9bn for Soleno and extreme hunger drug

Neurocrine Biosciences has agreed a $2.9bn deal to buy Soleno Therapeutics and its treatment for a rare, genetic form of severe obesity.

News

US pharma tariffs of up to 100% finalised by Trump

Trump signs his pharma tariffs executive order, which won't affect most large pharma groups but could deal a hefty blow to smaller companies.

News

Ambrosia's sweet $100m round, and other biofinancings

Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.

News

Immunovant's thyroid eye disease drug flunks pivotal trials

Immunovant shares were sliding today after it reported that FcRn blocker batoclimab failed a pair of phase 3 trials in thyroid eye disease.

Sanofi's bispecific lunsekimig has mixed readouts in phase 2

Amgen scores with new thyroid eye disease formulation

Neurocrine pays $2.9bn for Soleno and extreme hunger drug

US pharma tariffs of up to 100% finalised by Trump

Ambrosia's sweet $100m round, and other biofinancings

Immunovant's thyroid eye disease drug flunks pivotal trials

Amazon puts $100m into global health drive

Discover a new era of healthcare panel engagement: Grounded ...

pharma news

Editor's Picks